tbuckley/cabot-search huggingface dataset:
Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility in radical prostatectomy tissues.
Authors: Mohammed Alshalalfa, Harrison Tsai, Zaid Haddad, Ashley Ross, Jeffrey Karnes, Elai Davicioni, Edward M. Schaeffer, Tamara L. Lotan
Journal: Journal of Clinical Oncology (2016)

5055 Background: Small cell (SC) neuroendocrine carcinoma of the prostate has very poor prognosis and does not respond well to androgen receptor (AR)-targeted therapies. Neuroendocrine prostate carcinomas are increasingly recognized to show a spectrum of morphologic changes, and may not always be distinguishable from adenocarcinoma based on morphology alone. Here we hypothesize that SC carcinoma harbor a unique gene expression signature that, when measured in primary prostatic adenocarcinoma, may help guide subsequent management. Methods: Whole genome expression profiles of12 morphologically-diagnosed SC carcinoma samples and 12 high risk adenocarcinoma retrieved from the Decipher GRID to define SC Genomic Fingerprint (SCGFt) through differential expression analysis. The SCGFt was first validated in mCRPC and NE cohorts, then translated to a genomic score (SCGS) using UVA to weight SCGFt components. An additional 2,400 RP adenocarcinomas from the Decipher GRID were used to evaluate the utility of the SCGS for predicting outcome. Results: Based on genomic prognostic tests calculated using the Decipher assay including Decipher, Penney and microarray-derived Cell Cycle Progression, SC carcinomas have very poor prognosis compared to high grade adenocarcinomas. A total of 25 genes defined the SCGFt. PEG10, cell proliferation and RB1-loss program are the most overexpressed genes in SC and AR-related genes the most down-regulated. SCGS was generated for Prostate cancer cell lines and showed to be predictive of Abiraterone response. Evaluating SCGS in RP adenocarcinoma cohorts showed that patients with high SCGS are at higher risk of developing metastasis after RP in a natural history cohort or after adjuvant hormonal therapy based on Kaplan Meier analysis (both p < 0.001). SCGS was then generated for > 2,000 RP samples from prospective Decipher test showing 2% are likely to harbour small cells or NE-like expression profiles. Conclusions: SC carcinoma has a distinct genomic profile that may be useful for treatment management of patients with adenocarcinoma.
PKCA/AP-1 Drives Transcription of Interferon-Stimulated Genes and Mediates Cell-Autonomous Defense against Hepatitis E Virus
Authors: W. Wang, Y. Wang, X. Zhou, Y. Yin, L. Xu, Y. Debing, E. Herrera Carrillo, J. Brandsma, D. Sprengers, R. Poot, H. Metselaar, R. Smits, B. Berkhout, J. Neyts, M. Peppelenbosch, Q. Pan
Journal: Journal of Hepatology (2016)
Oral Medications Improve the Compliance to Regular Surveillance for Hepatocellular Carcinoma in Chronic Hepatitis B Patients
Authors: J.Y. Nam, J.-H. Lee, D.H. Lee, Y. Chang, H. Ahn, H. Cho, J.-J. Yoo, M. Lee, Y.Y. Cho, E. Cho, S.J. Yu, Y.J. Kim, J.-H. Yoon
Journal: Journal of Hepatology (2016)
Novel Hyperactive Transposons for Genetic Modification of Induced Pluripotent and Adult Stem Cells: A Non-Viral Paradigm for Coaxed Differentiation
Authors: E. Belay, J. Matrai, A. Acosta-Sanchez, L. Ma, M. Quattrocelli, L. Mates, P. Sancho-Bru, M. Geraerts, B. Yan, J. Vermeesch, M.Y. Rincon, E. Samara-Kuko, Z. Ivics, C.M. Verfaillie, M. Sampaolesi, Z. Izsvak, T. Vandendriessche, M.K. Chuah
Journal: Molecular Therapy (2010)
Restoration of Hydrogen Sulfide Production in Diabetic Mice Improves Reparative Function of Bone Marrow Cells
Authors: Zhongjian Cheng, Venkata Naga Srikanth Garikipati, Emily Nickoloff, Chunlin Wang, David J. Polhemus, Jibin Zhou, Cynthia Benedict, Mohsin Khan, Suresh K. Verma, Joseph E. Rabinowitz, David Lefer, Raj Kishore
Journal: Circulation (2016)

Bone marrow cell (BMC)-based treatment for critical limb ischemia in diabetic patients yielded a modest therapeutic effect resulting from cell dysfunction. Therefore, approaches that improve diabetic stem/progenitor cell functions may provide therapeutic benefits. Here, we tested the hypothesis that restoration of hydrogen sulfide (H2S) production in diabetic BMCs improves their reparative capacities.Mouse BMCs were isolated by density-gradient centrifugation. Unilateral hind limb ischemia was conducted in 12- to 14-week-old db/+ and db/db mice by ligation of the left femoral artery. The H2S level was measured by either gas chromatography or staining with florescent dye sulfidefluor 7 AM.Both H2S production and cystathionine γ-lyase (CSE), an H2S enzyme, levels were significantly decreased in BMCs from diabetic db/db mice. Administration of H2S donor diallyl trisulfide (DATS) or overexpression of CSE restored H2S production and enhanced cell survival and migratory capacity in high glucose (HG)-treated BMCs. Immediately after hind limb ischemia surgery, the db/+ and db/db mice were administered DATS orally and/or given a local intramuscular injection of green fluorescent protein-labeled BMCs or red fluorescent protein-CSE-overexpressing BMCs (CSE-BMCs). Mice with hind limb ischemia were divided into 6 groups: db/+, db/db, db/db+BMCs, db/db+DATS, db/db+DATS+BMCs, and db/db+CSE-BMCs. DATS and CSE overexpression greatly enhanced diabetic BMC retention in ischemic hind limbs followed by improved blood perfusion, capillary/arteriole density, skeletal muscle architecture, and cell survival and decreased perivascular CD68+ cell infiltration in the ischemic hind limbs of diabetic mice. It is interesting to note that DATS or CSE overexpression rescued high glucose-impaired migration, tube formation, and survival of BMCs or mature human cardiac microvascular endothelial cells. Moreover, DATS restored nitric oxide production and decreased endothelial nitric oxide synthase phosphorylation at threonine 495 levels in human cardiac microvascular endothelial cells and improved BMC angiogenic activity under high glucose condition. Last, silencing CSE by siRNA significantly increased endothelial nitric oxide synthase phosphorylation at threonine 495 levels in human cardiac microvascular endothelial cells.Decreased CSE-mediated H2S bioavailability is an underlying source of BMC dysfunction in diabetes mellitus. Our data indicate that H2S and overexpression of CSE in diabetic BMCs may rescue their dysfunction and open novel avenues for cell-based therapeutics of critical limb ischemia in diabetic patients.
BPTF Depletion Enhances T-cell–Mediated Antitumor Immunity
Authors: Kimberly Mayes, Suehyb G. Alkhatib, Kristen Peterson, Aiman Alhazmi, Carolyn Song, Vivian Chan, Tana Blevins, Mark Roberts, Catherine I. Dumur, Xiang-Yang Wang, Joseph W. Landry
Journal: Cancer Research (2016)

Genetic studies in fruit flies have implicated the chromatin remodeling complex nucleosome remodeling factor (NURF) in immunity, but it has yet to be studied in mammals. Here we show that its targeting in mice enhances antitumor immunity in two syngeneic models of cancer. NURF was disabled by silencing of bromodomain PHD-finger containing transcription factor (BPTF), the largest and essential subunit of NURF. We found that both CD8+ and CD4+ T cells were necessary for enhanced antitumor activity, with elevated numbers of activated CD8+ T cells observed in BPTF-deficient tumors. Enhanced cytolytic activity was observed for CD8+ T cells cocultured with BPTF-silenced cells. Similar effects were not produced with T-cell receptor transgenic CD8+ T cells, implicating the involvement of novel antigens. Accordingly, enhanced activity was observed for individual CD8+ T-cell clones from mice bearing BPTF-silenced tumors. Mechanistic investigations revealed that NURF directly regulated the expression of genes encoding immunoproteasome subunits Psmb8 and Psmb9 and the antigen transporter genes Tap1 and Tap2 The PSMB8 inhibitor ONX-0914 reversed the effects of BPTF ablation, consistent with a critical role for the immunoproteasome in improving tumor immunogenicity. Thus, NURF normally suppresses tumor antigenicity and its depletion improves antigen processing, CD8 T-cell cytotoxicity, and antitumor immunity, identifying NURF as a candidate therapeutic target to enhance antitumor immunity. Cancer Res; 76(21); 6183-92. ©2016 AACR.
Doctors could be asked to declare private income, NHS England says
Authors: Abi Rimmer
Journal: BMJ (2016)

Doctors could be asked to declare how much they have earnt from private practice, under proposals set out by NHS England.

The plans were included in a wider NHS England consultation on proposals designed to strengthen the management of conflicts of interest, which was published on 19 September.1

Under the proposals, clinical staff would be required to declare their earnings from private practice and state whether they earnt less than £50 000, less than £100 000, or more than £100 000. This information would then be included on their employers’ register …
Fibrinolysis with Adjunctive Enoxaparin with or without Abciximab-Results of the ENTIRE-TIMI 23 Trial
Authors: EM Antman, CM Gibson, Hein Heidbuchel, KC Schuhwerk, G Pisapia, Lelouer, F Bigonzi, E Braunwald, Frans Van de Werf
Journal: Circulation (2001)
PWE-096 Non-invasive assessment of disease severity in primary sclerosing cholangitis (psc): clinical scores, transient elastography (te) and the enhanced liver fibrosis (elf) test: Abstract PWE-096 Table 1
Authors: F Saffioti, M Vesterhus, A Telese, G Mazza, D Roccarina, M Rosselli, W Jonasson, A Parés, TH Karlsen, W Rosenberg, M Pinzani, A Marshall, D Thorburn
Journal: Gut (2015)

<h3>Introduction</h3> In PSC it has been believed that staging fibrosis is unhelpful due to the patchy nature of the condition, hence liver biopsy is rarely performed. Emerging data indicates that TE correlates well with fibrosis stage on liver histology and that both TE and the ELF test provide prognostic information in PSC. Thus far there has been no direct comparison of ELF testing and TE. Here we present a comparison of clinical scores, TE and the ELF test in patients with PSC. <h3>Method</h3> Patients with large-duct PSC had TE [Fibroscan® (Echosens): 10 valid measurements and a success rate &gt;60% after 3 hrs fasting] and serum stored at the same visit to the Royal Free, London and the Hospital Clínic, Barcelona (Jun 2010–Feb 2015). Full patient demographics and clinical outcomes were recorded. Clinical scores of disease severity (APRI and Mayo risk score) were obtained on the day of assessment. Stored sera were tested for ELF [ADVIA Centauro® XP system (Siemens Diagnostics). Spearman–s rank correlation was used due to the non-normal distribution of measures. <h3>Results</h3> 39 [1 autoimmune overlap, 28(72%) male] PSC patients [mean (±SD): age 50(±14) yrs; age at diagnosis 42(±14) yrs; time from diagnosis of 7.8(±7.1) yrs] were evaluated. 28 patients (80%) were diagnosed with IBD: 21 ulcerative colitis, 6 Crohn’s disease, 1 indeterminate colitis. There were no significant differences in ELF, TE or age between UK and Barcelona patients. Fibroscan correlated with ELF with a Spearman–s rho 0.676 p &lt; 0.001. Similarly, a strong correlation for both ELF and Fibroscan with Mayo [rho 0.836 (p &lt; 0.001) and rho 0.771 (p &lt; 0.001), respectively] and APRI [rho 0.766 (p &lt; 0.001) and rho 0.755 (p &lt; 0.001), respectively] scores was found. <h3>Conclusion</h3> A significant correlation between liver stiffness measured by TE, ELF test, APRI and Mayo risk score is here demonstrated for the first time in patients with PSC. Our results suggest that while the process of fibrosis progression in PSC is poorly understood, non-invasive tests validated in other chronic liver diseases perform consistently in patients affected and should be further evaluated as tools for staging the disease, monitoring disease progression and prognosis and may provide much needed surrogate end points for clinical trials in PSC. <h3>Disclosure of interest</h3> F. Saffioti: None Declared, M. Vesterhus: None Declared, A. Telese: None Declared, G. Mazza: None Declared, D. Roccarina: None Declared, M. Rosselli: None Declared, W. Jonasson: None Declared, A. Parés: None Declared, T. Karlsen: None Declared, W. Rosenberg: None Declared, M. Pinzani: None Declared, A. Marshall: None Declared, D. Thorburn Grant/Research Support from: Boston Scientific to fund a clinical research fellow.
Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF
Authors: Kenya Kusunose, Yuta Torii, Hirotsugu Yamada, Susumu Nishio, Yukina Hirata, Hiromitsu Seno, Yoshihito Saijo, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata
Journal: JACC. Cardiovascular imaging (2016)
Timing of Initiation of Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Authors: Christophe Vinsonneau, Mehran Monchi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Utility of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) for Advanced Fibrosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
Authors: M. Korenaga, K. Korenaga, M. Imamura, Y. Aoki, M. Sugiyama, T. Kanto, M. Mizokami
Journal: Journal of Hepatology (2016)
Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Authors: Pier Luigi Zinzani, Vincent Ribrag, Craig H. Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Ellen Snyder, Patricia Marinello, Margaret A. Shipp, Philippe Armand
Journal: Blood (2015)
Establishment of a Novel Cell Line of Plasmablastic Lymphoma with Loss of p16 Tumor Suppressor Protein and Overexpression of MDR
Authors: Eri Matsuki, Yoshitaka Miyakawa, Shuichi Asakawa, Yuiko Tsukada, Kenji Yokoyama, Jun Kudoh, Shinichiro Okamoto
Journal: Blood (2010)
Decreasing Incidence of Cancer after Liver Transplantation - A Nordic Population-Based Study
Authors: F. Åberg, A. Nordin, E. Pukkala, C.R. Pedersen, H.H. Storm, A. Rasmussen, W. Bennet, M. Olausson, H. Wilczek, B.-G. Ericzon, S. Tretli, P.-D. Line, T.H. Karlsen, K.M. Boberg, H. Isoniemi
Journal: Journal of Hepatology (2016)
Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis
Authors: E.J. Gane, M. Nguyen, P. Kwo, K. Kowdley, N. Reau, I. Jacobson, M. Curry, B. Pearlman, O. Khalid, G. Everson, S. Gordon, J. Poulos, A. Sheikh, D. Bernstein, J.C. Yang, L.M. Stamm, D. An, H. Dvory-Sobol, D.M. Brainard, J.G. McHutchison, M. Tong, N. Tsai, K.L. Beavers, M. Rabinovitz, M. Shiffman, C. Stedman, E. Lawitz
Journal: Journal of Hepatology (2016)
The CXCL12/CXCR7 System Mediates Migration and Survival of Cholangiocarcinoma (CCA) Cells through Interaction with CXCR4 and Barrestin-2
Authors: A. Gentilini, K. Rombouts, M. Pinzani, C. Raggi, P. Invernizzi, C. Raschioni, F. Marra
Journal: Journal of Hepatology (2016)
Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL)
Authors: Luis F. Porrata, Kay M. Ristow, Thomas M. Habermann, Thomas E Witzig, Joseph P. Colgan, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Grzegorz S. Nowakowski, Carrie A. Thompson, Svetomir N. Markovic
Journal: Blood (2012)
Cancer Therapy: Biomaterials for Abrogating Metastasis: Bridging the Gap between Basic and Translational Research (Adv. Healthcare Mater. 18/2016)
Authors: João Conde, Noam Shomron, Natalie Artzi
Journal: Advanced Healthcare Materials (2016)

Nanomaterials can be used to probe, sense and treat metastasis while facilitating in depth understanding of disease associated mechanisms. Leveraging the potential of nanomedicine to combat cancer spread at each stage of the metastatic process while exploiting different administration routes may facilitate the development of new cancer therapeutic approaches and improve (pre)-clinical outcomes. Natalie Artzi and co-workers outline the current challenges in this research field on page 2312.
Evolution of Digestive Enzymes and RNASE1 Provides Insights into Dietary Switch of Cetaceans
Authors: Zhengfei Wang, Shixia Xu, Kexing Du, Fang Huang, Zhuo Chen, Kaiya Zhou, Wenhua Ren, Guang Yang
Journal: Molecular Biology and Evolution (2016)

Although cetaceans (whales, porpoises, and dolphins) have multi-chambered stomachs, feeding habits of modern cetaceans have dramatically changed from herbivorous to carnivorous. However, the genetic basis underlying this dietary switch remains unexplored. Here, we present the first systematic investigation of 10 digestive enzymes genes (i.e., CYP7A1, CTRC, LIPC, LIPF, PNLIP, PGC, PRSS1, SI, SLC5A1, and TMPRSS15) of representative cetaceans, and the evolutionary trajectory of RNASE1 in cetartiodactylans. Positive selections were detected with proteinases (i.e., CTRC, PRSS1, and TMPRSS15) and lipases (i.e., CYP7A1, LIPF, and PNLIP) suggesting that cetaceans have evolved an enhanced digestion capacity for proteins and lipids, the major nutritional components of their prey (fishes and invertebrates). In addition, it was found that RNASE1 gene duplicated after the cetartiodactylan speciation and two independent gene duplication events took place in Camelidae and Ruminantia. Positive selection was detected with RNASE1 of Camelidae and Bovidae, suggesting enhanced digestive efficiency in the ruminants. Remarkably, even though the ancestors of cetaceans were terrestrial artiodactyls that are herbivorous, modern cetaceans lost the pancreatic RNASE1 copy with digestive function, which is in accordance with the dietary change from herbivorous to carnivorous. In sum, this is the first study that provides new insights into the evolutionary mechanism of dietary switch in cetaceans.
Metallic surface treatment using electrochemical polishing decreases thrombogenicity and neointimal hyperplasia after coronary stent implantation in a porcine model
Authors: I. De Scheerder, K. Wang, J. Sohier, E. Verbeken, X.R. Zhou, L. Frooyen, J. Van Humbeeck, F. Van de Werf
Journal: Journal of the American College of Cardiology (1998)
P0916 : Emergence of hepatitis C virus genotype recombinant forms 2K/1B in Georgia
Authors: M. Zakalashvili, M. Weizenegger, S. Kavsadze, K. Kvatadze, G. Basheleishvili, T. Phirtskhalaishvili, T. Dzagania, J. Zarqua, L. Zangurashvili, N. Kankia, N. Jashiashvili, M. Lomidze, V. Kerashvili, M. Zhamutashvili, N. Abramishvili, D. Metr
Journal: Journal of Hepatology (2015)
The effect of smoking on lung function: a clinical study of adult-onset asthma
Authors: Minna Tommola, Pinja Ilmarinen, Leena E. Tuomisto, Jussi Haanpää, Terhi Kankaanranta, Onni Niemelä, Hannu Kankaanranta
Journal: European Respiratory Journal (2016)

The aim of this study was to evaluate the effect of smoking on lung function decline in adult-onset asthma in a clinical, 12-year follow-up study.In the Seinäjoki Adult Asthma Study, 203 patients were followed for 12 years (1999-2013) after diagnosis of new-onset adult asthma. Patients were divided into two groups based on smoking history: <10 or ≥10 pack-years. Spirometry evaluation points were: 1) baseline, 2) the maximum lung function during the first 2.5 years after diagnosis (Max0-2.5) and 3) after 12 years of follow-up.Between Max0-2.5 and follow-up, the median annual decline in absolute forced expiratory volume in 1 s (FEV1) was 36 mL in the group of patients with <10 pack-years of smoking and 54 mL in those with smoking history ≥10 pack-years (p=0.003). The annual declines in FEV1 % pred (p=0.006), forced vital capacity (FVC) (p=0.035) and FEV1/FVC (p=0.045) were also accelerated in the group of patients with ≥10 pack-years smoked. In multivariate regression analysis, smoking history ≥10 pack-years became a significant predictor of accelerated decline in FEV1Among patients with clinically defined adult-onset asthma, smoking history ≥10 pack-years is associated with accelerated loss of lung function.
Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma
Authors: Jennifer R Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Arthur P. DeCillis, Kevin Rockich, Coumaran Egile, Adrianne Kelly, Yi Xu, Joanne Lager, Farrukh T Awan
Journal: Blood (2011)
Sequential immune checkpoint inhibition with concurrent bevacizumab for relapsed glioblastoma: A single centre experience.
Authors: Nicholas Fraser Brown, Thomas Carter, Heather May Shaw, Denise Cohn-Brown, Kerry Chester, Paul James Mulholland
Journal: Journal of Clinical Oncology (2016)

e13514 Background: Median survival in relapsed glioblastoma is six months, and there are no established second-line therapies. There is increasing interest in the role of immunotherapy in glioblastoma but whilst immune checkpoint inhibitors are now routinely being used in other tumour types, the role of these drugs in glioblastoma is not yet formally evaluated. Methods: We retrospectively identified patients with glioblastoma treated with ipilimumab followed by pembrolizumab at progression, with concurrent bevacizumab and GM-CSF given throughout. Safety, tolerability and treatment responses were reviewed for all patients. Results: Four patients were identified: 3 male and 1 female aged between 23 and 55 years. All patients were treated for relapsed glioblastoma. All patients received 4 cycles of ipilimumab at first relapse, and subsequent pembrolizumab at second relapse (3 patients received 9 cycles, 1 patient received 10 cycles). One patient received concurrent lomustine chemotherapy and all patients received concurrent bevacizumab and GM-CSF. Adverse events attributed to ipilimumab: 2 patients experienced grade 1 fatigue, 1 patient had grade 2 diarrhoea, and 1 patient had a grade 2 perianal fistula. No adverse events were noted with pembrolizumab. Response data: 2 patients had a partial response on ipilimumab, one of whom had a further partial response during pembrolizumab treatment. One patient had disease progression on ipilimumab but stable disease on pembrolizumab. The final patient had stable disease on both ipilimumab and pembrolizumab. Conclusions: Administering sequential checkpoint inhibitors appears safe and tolerable in patients with glioblastoma and there is some evidence of clinical efficacy. Formal clinical trials are needed to determine efficacy and establish the role of immune checkpoint inhibition in this devastating disease.
Ultrasonic strain rate imaging can predict the recovery of function after acute myocardial infarction and assess the transmurality of scar in chronic infarctions
Authors: F Weidemann, C Wacker, A Rauch, F Fidler, WR Bauer, GR Sutherland, Bart Bijnens, G Ertl, W Voelker, JM Strotmann
Journal: Circulation (2004)